Annual Accounts Receivable
$73.39 M
+$32.95 M+81.46%
31 December 2023
Summary:
Ultragenyx Pharmaceutical annual accounts receivable is currently $73.39 million, with the most recent change of +$32.95 million (+81.46%) on 31 December 2023. During the last 3 years, it has risen by +$44.96 million (+158.12%). RARE annual accounts receivable is now at all-time high.RARE Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$93.30 M
-$12.68 M-11.97%
30 September 2024
Summary:
Ultragenyx Pharmaceutical quarterly accounts receivable is currently $93.30 million, with the most recent change of -$12.68 million (-11.97%) on 30 September 2024. Over the past year, it has increased by +$19.91 million (+27.13%). RARE quarterly accounts receivable is now -11.97% below its all-time high of $105.98 million, reached on 30 June 2024.RARE Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RARE Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +27.1% |
| 3 y3 years | +158.1% | +228.2% |
| 5 y5 years | +123.5% | +184.1% |
RARE Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +158.1% | -12.0% | +228.9% |
| 5 y | 5 years | at high | +217.8% | -12.0% | +526.5% |
| alltime | all time | at high | -12.0% |
Ultragenyx Pharmaceutical Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $93.30 M(-12.0%) |
| June 2024 | - | $105.98 M(+5.7%) |
| Mar 2024 | - | $100.25 M(+36.6%) |
| Dec 2023 | $73.39 M(+81.5%) | $73.39 M(-7.4%) |
| Sept 2023 | - | $79.26 M(+12.4%) |
| June 2023 | - | $70.52 M(+64.0%) |
| Mar 2023 | - | $42.99 M(+6.3%) |
| Dec 2022 | $40.45 M(+42.3%) | $40.45 M(+29.8%) |
| Sept 2022 | - | $31.16 M(-16.2%) |
| June 2022 | - | $37.21 M(+31.2%) |
| Mar 2022 | - | $28.37 M(-0.2%) |
| Dec 2021 | $28.43 M(+23.1%) | $28.43 M(+12.0%) |
| Sept 2021 | - | $25.38 M(+2.7%) |
| June 2021 | - | $24.72 M(-1.2%) |
| Mar 2021 | - | $25.03 M(+8.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2020 | $23.09 M(-29.7%) | $23.09 M(-16.8%) |
| Sept 2020 | - | $27.76 M(+86.4%) |
| June 2020 | - | $14.89 M(-49.2%) |
| Mar 2020 | - | $29.33 M(-10.7%) |
| Dec 2019 | $32.84 M(+157.8%) | $32.84 M(+42.1%) |
| Sept 2019 | - | $23.12 M(+10.6%) |
| June 2019 | - | $20.90 M(+33.7%) |
| Mar 2019 | - | $15.63 M(+22.7%) |
| Dec 2018 | $12.74 M(+146.3%) | $12.74 M(+39.2%) |
| Sept 2018 | - | $9.15 M(-47.5%) |
| June 2018 | - | $17.43 M(+374.7%) |
| Mar 2018 | - | $3.67 M(-29.0%) |
| Dec 2017 | $5.17 M(>+9900.0%) | $5.17 M(>+9900.0%) |
| Dec 2016 | $0.00 | $0.00(-100.0%) |
| Sept 2013 | - | $38.00 K |
FAQ
- What is Ultragenyx Pharmaceutical annual accounts receivable?
- What is the all time high annual accounts receivable for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly accounts receivable year-on-year change?
What is Ultragenyx Pharmaceutical annual accounts receivable?
The current annual accounts receivable of RARE is $73.39 M
What is the all time high annual accounts receivable for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual accounts receivable is $73.39 M
What is Ultragenyx Pharmaceutical quarterly accounts receivable?
The current quarterly accounts receivable of RARE is $93.30 M
What is the all time high quarterly accounts receivable for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly accounts receivable is $105.98 M
What is Ultragenyx Pharmaceutical quarterly accounts receivable year-on-year change?
Over the past year, RARE quarterly accounts receivable has changed by +$19.91 M (+27.13%)